Definition

According to the Montreal Agreement, gastroesophageal reflux is characterized by

symptoms and / or structural changes in the esophagus caused by reflux

stomach contents into the esophagus and are associated with deterioration in the quality of life of patients.

Pathogenesis

The cause of reflux is multifactorial, i.e. there are usually several factors involved in weakening the reflux barrier.

The most important is the spontaneous relaxation of the lower esophageal sphincter muscle. Other contributing factors include septal hernia, impaired esophageal motility, obesity, increased intra-abdominal pressure, disturbed gastric emptying, etc.

The whole process is complex and there is no correlation between the extent of the reflux on the one hand and the intensity of the symptoms on the other.

It is worth noting that 10% of patients with reflux form a metaplastic, acid-resistant, mucosa in the lower esophagus (Barrett esophagus), and are at potentially increased risk of developing malignancy (adenocarcinoma).

Diagnosis

The most important diagnostic measure is to obtain a detailed medical history.

In addition, gastroscopy plays an important role, which can reveal lesions such as reflux esophagitis including its complications (stenosis, ulcer, bleeding). It is worth noting that in about 60% of cases, however, there are no mucosal lesions (the so-called non-corrosive reflux, NERD).

 Gastroscopy is also very important in the diagnosis of Barrett’s esophagus, as this can only be done endoscopically (with biopsies). To detect its neoplastic changes in patients with Barrett’s esophagus, special chromoendoscopy and magnification endoscopy techniques are used that give us valuable information.

Functional diagnostic tests also include impedance Ph-measurement which allows the differentiation between acidic and non-acidic reflux, especially in treatment-resistant patients.

Treatment

According to international guidelines, treatment with proton pump inhibitors (PPIs) is the treatment of choice in patients with reflux disease. Thus, depending on the severity of esophagitis, a cure is seen in 80-95% of cases within about six to eight weeks.

For long-term prophylaxis against relapse, PPIs represent the predominant form of treatment, but at a reduced dosage. In patients with extra-esophageal manifestations such as cough, throat clearing, laryngitis the effectiveness of PPIs is the subject of modern studies.

Surgical treatment of gastroesophageal reflux disease is effective for a small portion of the population. In the context of surgeries that are currently performed exclusively laparoscopically, the functionality of the lower esophageal sphincter is restored (partially or completely) by vaulting.

Newer surgeries such as electrical stimulation or placement of a magnetic ring around the lower esophageal sphincter are expected to be evaluated in long-term studies.

Barrett oesophagus is the principal risk factor for oesophageal cancer. When symptoms remain refractory to acid suppression, eosinophilic oesophagitis should also be considered.

Key figures

  • Barrett is the principal risk factor for oesophageal adenocarcinoma
  • Absolute annual progression risk for an individual patient is low
  • Surveillance interval depends on segment length and presence of dysplasia
  • Dysplastic Barrett is treated by resection plus ablation of the remaining segment

Frequently asked questions

Does Barrett oesophagus mean cancer will develop?

No. Barrett is the main risk factor for oesophageal adenocarcinoma, but the absolute risk for an individual patient is low. The purpose of scheduled surveillance is to detect dysplasia, which can then be treated endoscopically and completely, before invasive cancer appears.

How often is surveillance endoscopy performed?

The interval depends on the length of the Barrett segment and on whether dysplasia is present, and is set by guideline rather than by symptoms. Symptom control with acid suppression does not remove the need for surveillance, because the metaplastic epithelium persists regardless of how the patient feels.

Can Barrett be removed?

Dysplastic Barrett is treated endoscopically, with resection of any visible lesion followed by ablation of the remaining segment, so that no epithelium capable of progressing is left behind. Non-dysplastic Barrett is generally kept under surveillance rather than ablated.

Sources

Content last updated: September 2026 (14/09/2026).